Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
94 hedge funds and large institutions have $207M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 7 closing their positions.
186% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $1.25M
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 91 → 94 (+3)
29% less capital invested
Capital invested by funds: $291M → $207M (-$83.2M)
38% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 34
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.55M |
| 2 |
BlackRock
New York
|
+$1.42M |
| 3 |
Renaissance Technologies
New York
|
+$1.12M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$942K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.72M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.7M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.14M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$900K |
| 5 |
JP Morgan Chase
New York
|
-$793K |
EIGR Hedge Fund Activity: Q1 2021 in Review
94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2021, worth a combined $207M — down 29% from $291M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new EIGR positions and 7 closed out — a net gain of 3 holders — while 21 added to existing stakes and 34 trimmed.
The largest buyer was Ameriprise, adding an estimated $5.55M. The largest seller was Assenagon Asset Management, cutting an estimated $1.72M.
- 94 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2021, up from 91 in Q4 2020.
- Funds reported $207M of Eiger BioPharmaceuticals, Inc. stock for Q1 2021, down 29% quarter-over-quarter.
- 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2021 and 7 closed out, a net change of +3 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2021 was Ameriprise, an estimated $5.55M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2021 was Assenagon Asset Management, an estimated $1.72M sold.
Based on aggregated 13F filings for Q1 2021.